Oncology CME Sample Question 1
A 65-year-old man presents with a screening PSA 380, bone scan shows 4 osseous metastases in the spine and metastases involving the right femur and calvarium. CT imaging does not identify any soft-tissue metastases. Bone biopsy confirms prostate adenocarcinoma.
What treatment option would you recommend?
- AAndrogen suppression
- BAndrogen suppression plus low-dose prostate radiation therapy
- CAndrogen suppression plus bicalutamide
- DAndrogen suppression plus abiraterone plus prednisone
Oncology CME Sample Question 2
A 69-year-old man presents with mCRPC with bone involvement. He was previously treated with ADT plus abiraterone acetate plus prednisone, and most recently had progressed with a rising PSA and new bone lesions. Next-generation sequencing reveals a BRCA2 mutation. You advised him to discontinue abiraterone. Which is not an appropriate treatment option?
- AStart docetaxel
- BStart enzalutamide plus talazoparib
- CStart Lu177-PSMA617
- DStart Olaparib +/- abiraterone
Oncology CME Sample Question 3
A 68-year-old man presents to you with mCRPC having previously progressed on prior ADT plus abiraterone, followed by docetaxel. Next-generation sequencing reveals a pathogenic somatic ATM alteration. PSMA is expressed in all bone lesions but is absent in a 0.9 cm liver lesion. Which option would you choose?
- AStart Lu177-PSMA617
- BEnzalutamide plus talazoparib
- CRadium-223
- DOlaparib
- EB or C
Results
Provide your email to see your results and get exclusive discounts on additional board review questions.